Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: A prospective study

Nephrology Dialysis Transplantation

Volumn 12, Issue 12, 1997, Pages 2597-2602

  Jungers, P ^a   Massy, Z A ^a   Nguyen Khoa, T ^a   Fumeron, C ^a   Labrunie, M ^a   Lacour, B ^a   Descamps Latscha, B ^a   Man, N K ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Accelerated atherosclerosis; Atherogenic risk factors; Cardiovascular accidents; Cerebral infarction; Chronic renal failure; Myocardial infarction

Indexed keywords

APOLIPOPROTEIN B; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; BRAIN INFARCTION; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; DISEASE SEVERITY; FEMALE; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; HEART INFARCTION; HUMAN; INCIDENCE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SMOKING; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; UREMIA;

EID: 0030670011     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/12.12.2597     Document Type: Article

References (42)

1. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 697-701
2. Raine AEG, Margreiter R, Brunner FP et al. Report on management of renal failure in Europe, XXII, 1991. Nephrol Dial Transplant 1992; 7[Suppl 2]: 7-35
3. USRDS 1994 Annual Report. Am J Kidney Dis 1994; 24[Suppl 2]: S88-S95
4. Parfrey PS, Harnett JD. Long-term cardiac morbidity and mortality during dialysis therapy. Adv Nephrol Necker Hosp 1994; 23: 311-30
5. Ritz E, Deppisch R, Stier E, Hansch G. Atherogenesis and cardiac death: are they related to dialysis procedure and biocompatibility? Nephrol Dial Transplant 1994; 9[Suppl 2]: 165-172
6. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray D, Barre PE. Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int 1996; 49: 1428-1434
7. London GM, Drüeke TB. Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int 1997; 51: 1678-1695
8. Rostand SG, Kirk KA, Rutsky EA. Relationship of coronary risk factors to hemodialysis-associated ischemic heart disease. Kidney Int 1982; 22: 304-308
9. Lameire N, Bernaert P, Lambert MC, Vijt D. Cardiovascular risk factors and their management in patients on continuous ambulatory peritoneal dialysis. Kidney Int 1994; 46[Suppl 48]: S31-S38
10. Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996; 7: 158-165
11. ENIM 84 national survey. Frequency and conditions of hospitalization of recent myocardial infarcts in France. Arch Mal Coeur Vaiss (Paris) 1987; 80: 1853-1863
12. Rostand SG, Kirk KA, Rutsky EA. Dialysis-associated ischemic heart disease: insights from coronary angiography. Kidney Int 1984; 25: 653-659
13. Massy Z, Jungers P, Roulet JB, Drücke T, Lacour B. Disturbances of apolipoprotein distribution in lipoproteins of uremic patients. J Nephrol 1993; 6: 153-158
14. Massy ZA, Bader C, Chevalier A, et al. Serum lipoprotein (a) levels in chronic renal failure and renal transplant patients. J Nephrol 1994; 7: 229-236
15. Massy ZA, Chadefaux-Vekemans B, Chevalier A. et al. Hyperhomocysteinaemia: a significant risk factor for cardiovascular disease in renal transplant recipients. Nephrol Dial Transplant 1994; 9: 1103-1108
16. Nauck M, Kramerguth A, Bartens W, Marz W, Wieland H, Wanner C. Is the determination of LDL cholesterol according to Friedewald accurate in CAPD and HD patients? Clin Nephrol 1996; 46: 319-325
17. Foley RN, Parfrey PS, Hefferton D, Singh I, Simms A, Barrett BJ. Advance prediction of early death in patients starting maintenance dialysis. Am J Kidney Dis 1994; 23: 836-845
18. Brown JH, Hunt LP, Vites NP, Short CD, Gokal R, Mallick NP. Comparative mortality from cardiovascular disease in patients with chronic renal failure. Nephrol Dial Transplant 1994; 9: 1136-1142
19. Wheeler DC. Cardiovascular disease in patients with chronic renal failure. Lancet 1996; 348: 1673-1674
20. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992; 152: 56-64
21. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med 1993; 8,153; 598-615
22. Charra B, Calemard E, Ruffet M, et al. Survival as an index of adequacy of dialysis. Kidney Int 1992; 41: 1286-1291
23. Duthie GG, Arthur JR, Beattie JA, et al. Cigarette smoking, antioxidants, lipid peroxidation, and coronary heart disease. Ann N Y Acad Sci 1993; 686: 120-129
24. Maggi E, Bellazzi R, Falaschi F, et al. Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis? Kidney Int 1994; 45: 876-883
25. Grützmacher P, März W, Peschke B, Gross W, Schoeppe W. Lipoproteins and apolipoproteins during the progression of chronic renal disease. Nephron 1988; 50: 103-111
26. Attman PO, Alaupovic P, Tavella M, Knight-Gibson C. Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure. Nephrol Dial Transplant 1996; 11: 63-69
27. Avram MM, Goldwasser P, Burrell DE, Antignani A, Fein PA, Mittman N. The uremic dyslipidemia: a cross-sectional and longitudinal study. Am J Kidney Dis 1992; 20: 324-335
28. Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992; 86: 475-482
29. Webb AT, Reavely DA, O'Donnell M, O'Connor B, Seed M, Brown EA. Lipids and lipoprotein(a) as risk factors for vascular disease in patients on renal replacement therapy. Nephrol Dial Transplant 1994; 9: 354-357
30. Kronenberg F, Kathrein H, König P, et al. Apolipoprotein (a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. Arterioscler Thromb 1994; 14: 1405-1411
31. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-505
32. Gris JC, Branger B, Vecina F, Al Sabadani B, Fourcade J, Schved JF. Increased cardiovascular risk factors and features of endothelial activation and dysfunction in dialyzed uremic patients. Kidney Int 1994; 46: 807-813
33. Tomura S, Nakamura V, Doi M, et al. Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 1996; 27: 848-854
34. Descamps-Latscha B, Herbelin A, Nguyen AT, et al. Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes. J Immunol 1995; 154: 882-892
35. Chauveau P, Chadefaux B, Coudé M, et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 1993; 43[Suppl 41]: S72-S77
36. Bachmann J, Tepel M, Raidt H et al. Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 1995; 6: 121-125
37. Orth SR, Ritz E, Schrier RW. The renal risks of smoking. Kidney Int 1997; 51: 1669-1677
38. Perry RJ, Griffiths W, Dextraze P, Solomon RJ, Trebbin WM. Elevated nicotine levels in patients undergoing hemodialysis. A role in cardiovascular mortality and morbidity? Am J Med 1984; 76: 241-246
39. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123: 754-762
40. Massy ZA, Ma JZ, Louis TA, Kasiske BL Lipid-lowering therapy in patients with renal disease. Kidney Int 1995; 48: 188-198
41. Chauveau P, Chadefaux B, Coudé M, Aupetit J, Kamoun P, Jungers P. Long-term folic acid (but not pyridoxine) supplementation lowers elevated plasma homocysteine level in chronic renal failure. Miner Electrolyte Metab 1996; 22: 106-109
42. Janssen MJFM, Van Guldener C, De Jong GMT, Van den Berg M, Stehouwer CDA, Donker AJM. Folic acid treatment of hyperhomocysteinemia in dialysis patients. Miner Electrolyte Metab 1996; 22: 110-114